| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
35,530,000 |
| Market
Cap: |
296.85(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.43 - $11.75 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Mind Medicine Mindmed is a clinical stage biopharmaceutical company developing products to treat brain health disorders, with a focus on psychiatry, addiction, pain and neurology. Co.'s drug candidates include: MM-120, which is a proprietary, pharmaceutically optimized form of lysergide, and is being developed for the treatment of generalized anxiety disorder; MM-110, which is its proprietary form of 18-methoxycoronaridine, a congener of ibogaine, that is being developed for the treatment of opioid withdrawal; and MM-402, which is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine, that is developed for the treatment of main symptoms of autism spectrum disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
23,097 |
48,760 |
128,859 |
316,555 |
| Total Sell Value |
$219,422 |
$312,579 |
$590,703 |
$820,459 |
| Total People Sold |
2 |
3 |
3 |
3 |
| Total Sell Transactions |
2 |
5 |
12 |
34 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barrow Robert |
Chief Executive Officer |
• • – |
2022-06-16 |
4 |
S |
$0.70 |
$14,893 |
D/D |
(21,275) |
3,955,619 |
|
- |
|
| Krebs Andreas |
Director |
– • – |
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
21,552 |
21,552 |
|
- |
|
| Vallone Carol A |
Director |
– • – |
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
43,104 |
43,104 |
|
- |
|
| Makes Brigid |
Director |
– • – |
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
64,656 |
158,706 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-05-27 |
4 |
S |
$0.82 |
$7,835 |
D/D |
(9,555) |
4,077,719 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-05-25 |
4 |
S |
$0.77 |
$14,180 |
D/D |
(18,415) |
3,976,894 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-05-25 |
4 |
S |
$0.77 |
$6,346 |
D/D |
(8,242) |
4,087,274 |
|
- |
|
| Greenway Schond L. |
Chief Financial Officer |
• – – |
2022-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,270,000 |
1,270,000 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-05-18 |
4/A |
S |
$0.71 |
$13,453 |
D/D |
(18,948) |
3,995,309 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-05-15 |
4 |
D |
$0.82 |
$15,537 |
D/D |
(18,948) |
3,995,309 |
|
- |
|
| Makes Brigid |
Director |
– • – |
2022-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
67,678 |
94,050 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-04-26 |
4 |
D |
$0.81 |
$10,561 |
D/D |
(13,038) |
4,095,516 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-04-18 |
4 |
D |
$0.92 |
$17,581 |
D/D |
(19,110) |
4,014,257 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-03-28 |
4 |
D |
$1.17 |
$11,938 |
D/D |
(10,203) |
4,108,554 |
|
- |
|
| Wong Cynthia |
Chief Legal Officer&Secretary |
• – – |
2022-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,200,000 |
1,200,000 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
950,000 |
4,118,757 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,820,000 |
4,033,367 |
|
- |
|
| Wernli Miri Halperin |
Executive President |
• • – |
2022-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
600,000 |
1,275,000 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-03-15 |
4 |
D |
$1.00 |
$12,612 |
D/D |
(12,612) |
2,213,367 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2022-02-26 |
4 |
D |
$1.21 |
$142,953 |
D/D |
(118,143) |
3,168,757 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-02-15 |
4 |
D |
$1.35 |
$25,291 |
D/D |
(18,734) |
2,225,979 |
|
- |
|
| Liao Carrie |
VP, Controller&Acct Principal |
• – – |
2022-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
403,430 |
403,430 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2022-01-15 |
4 |
D |
$1.05 |
$199,801 |
D/D |
(190,287) |
2,244,713 |
|
- |
|
| Makes Brigid |
Director |
– • – |
2022-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
26,372 |
|
- |
|
| Wernli Miri Halperin |
Executive PresidentOfficer |
• • – |
2022-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
675,000 |
|
- |
|
79 Records found
|
|
Page 3 of 4 |
|
|
0.13 (1.52%) 
